227 related articles for article (PubMed ID: 34588252)
1. Protocol for the Stimulating β
Bubb KJ; Harmer JA; Finemore M; Aitken SJ; Ali ZS; Billot L; Chow C; Golledge J; Mister R; Gray MP; Grieve SM; Hamburg N; Keech AC; Patel S; Puttaswamy V; Figtree GA
BMJ Open; 2021 Sep; 11(9):e049858. PubMed ID: 34588252
[TBL] [Abstract][Full Text] [Related]
2. Cilostazol for intermittent claudication.
Bedenis R; Stewart M; Cleanthis M; Robless P; Mikhailidis DP; Stansby G
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003748. PubMed ID: 25358850
[TBL] [Abstract][Full Text] [Related]
3. The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study).
Clavijo LC; Caro J; Choi J; Caro JA; Tun H; Rowe V; Kumar SR; Shavelle DM; Matthews RV
Cardiovasc Revasc Med; 2023 Oct; 55():1-5. PubMed ID: 37142533
[TBL] [Abstract][Full Text] [Related]
4. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
Kurklinsky AK; Levy M
Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
Pouleur AC; Anker S; Brito D; Brosteanu O; Hasenclever D; Casadei B; Edelmann F; Filippatos G; Gruson D; Ikonomidis I; Lhommel R; Mahmod M; Neubauer S; Persu A; Gerber BL; Piechnik S; Pieske B; Pieske-Kraigher E; Pinto F; Ponikowski P; Senni M; Trochu JN; Van Overstraeten N; Wachter R; Balligand JL
ESC Heart Fail; 2018 Oct; 5(5):830-841. PubMed ID: 29932311
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study.
Besnier F; Sénard JM; Grémeaux V; Riédel M; Garrigues D; Guiraud T; Labrunée M
Trials; 2017 Aug; 18(1):373. PubMed ID: 28797281
[TBL] [Abstract][Full Text] [Related]
7. Motivating Structured walking Activity in people with Intermittent Claudication (MOSAIC): protocol for a randomised controlled trial of a physiotherapist-led, behavioural change intervention versus usual care in adults with intermittent claudication.
Bearne L; Galea Holmes M; Bieles J; Eddy S; Fisher G; Modarai B; Patel S; Peacock JL; Sackley C; Volkmer B; Weinman J
BMJ Open; 2019 Aug; 9(8):e030002. PubMed ID: 31446416
[TBL] [Abstract][Full Text] [Related]
8. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.
Poole J; Mavromatis K; Binongo JN; Khan A; Li Q; Khayata M; Rocco E; Topel M; Zhang X; Brown C; Corriere MA; Murrow J; Sher S; Clement S; Ashraf K; Rashed A; Kabbany T; Neuman R; Morris A; Ali A; Hayek S; Oshinski J; Yoon YS; Waller EK; Quyyumi AA
JAMA; 2013 Dec; 310(24):2631-9. PubMed ID: 24247554
[TBL] [Abstract][Full Text] [Related]
9. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
[TBL] [Abstract][Full Text] [Related]
10. Prostanoids for intermittent claudication.
Robertson L; Andras A
Cochrane Database Syst Rev; 2013 Apr; (4):CD000986. PubMed ID: 23633305
[TBL] [Abstract][Full Text] [Related]
11. MetfOrmin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC): randomized clinical trial protocol.
Reitz KM; Althouse AD; Forman DE; Zuckerbraun BS; Vodovotz Y; Zamora R; Raffai RL; Hall DE; Tzeng E
BMC Cardiovasc Disord; 2023 Jan; 23(1):38. PubMed ID: 36681798
[TBL] [Abstract][Full Text] [Related]
12. Cocoa to Improve Walking Performance in Older People With Peripheral Artery Disease: The COCOA-PAD Pilot Randomized Clinical Trial.
McDermott MM; Criqui MH; Domanchuk K; Ferrucci L; Guralnik JM; Kibbe MR; Kosmac K; Kramer CM; Leeuwenburgh C; Li L; Lloyd-Jones D; Peterson CA; Polonsky TS; Stein JH; Sufit R; Van Horn L; Villarreal F; Zhang D; Zhao L; Tian L
Circ Res; 2020 Feb; 126(5):589-599. PubMed ID: 32078436
[TBL] [Abstract][Full Text] [Related]
13. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Feasibility of Pain management and Patient Education for Physical Activity in Intermittent claudication (PrEPAID): protocol for a randomised controlled trial.
Abaraogu UO; Dall PM; Brittenden J; Stuart W; Tew GA; Godwin J; Seenan CA
Trials; 2019 Apr; 20(1):222. PubMed ID: 30992033
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study.
Mehta A; Mavromatis K; Ko YA; Rogers SC; Dhindsa DS; Goodwin C; Patel R; Martini MA; Prasad M; Mokhtari A; Hesaroieh IG; Frohwein SC; Kutner MH; Harzand A; Wells BJ; Duwayri Y; Alabi O; Rajani RR; Brewster LP; Waller EK; Quyyumi AA
Contemp Clin Trials; 2020 Apr; 91():105975. PubMed ID: 32145440
[TBL] [Abstract][Full Text] [Related]
17. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
18. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial.
McDermott MM; Ferrucci L; Tian L; Guralnik JM; Lloyd-Jones D; Kibbe MR; Polonsky TS; Domanchuk K; Stein JH; Zhao L; Taylor D; Skelly C; Pearce W; Perlman H; McCarthy W; Li L; Gao Y; Sufit R; Bloomfield CL; Criqui MH
JAMA; 2017 Dec; 318(21):2089-2098. PubMed ID: 29141087
[TBL] [Abstract][Full Text] [Related]
19. Short-duration aerobic high-intensity intervals versus moderate exercise training intensity in patients with peripheral artery disease: study protocol for a randomised controlled trial (the Angiof-HIIT Study).
Lanzi S; Pousaz A; Fresa M; Besson C; Desgraz B; Gremeaux-Bader V; Mazzolai L
BMJ Open; 2024 Apr; 14(4):e081883. PubMed ID: 38631833
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
